News List

Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI

Gilead Sciences, Inc. (Nasdaq: GILD) today presented additional results from the Phase 2/3 CAPELLA t

BeiGene Announces EMA Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with WM

On June 18, 2020, BeiGene, Ltd. (“BeiGene” or the “Company”), a commercial-stage biotechnology compa

VISEN Pharmaceutical's TransCon C-type natriuretic peptide Phase II clinical trial application approved in China

January 7, VISEN Pharmaceuticals announced that it had submitted TransCon CNP (TransCon C-type natri

Progress in the development of new and efficient diabetes treatment drugs

Recently, Wang Junfeng's research team from Hefei Institute of Material Science, Chinese Academy

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.

Merck's new HIV drug Pedro (Doravirin) was approved in China

Merck announced recentlythat its new HIV drug Pedro (doravirin tablets) has been officially approved

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shion

European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis

Gilead Sciences and Galapagos NV today announced that the European Commission (EC) has granted marke